钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并冠心病的研究进展  

Research Progress of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of T2DM Complicated with Coronary Heart Disease

作　　者：付子康 李海英[2] 李屏[1] FU Zikang;LI Haiying;LI Ping(Guizhou Medical University,Guiyang 550001,China;Guiyang First People's Hospital,Guiyang 550002,China)

机构地区：[1]贵州医科大学,贵州省贵阳市550001 [2]贵州省贵阳市第一人民医院,550002

出　　处：《中国全科医学》2022年第12期1493-1499,共7页Chinese General Practice

基　　金：贵阳市科技局贵阳市第一人民医院大健康科技合作项目(2019-9-8)。

摘　　要：糖尿病是冠心病的独立危险因素,两者在疾病进展中互为因果。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是治疗2型糖尿病(T2DM)的新型口服药物,通过阻断肾近曲小管对葡萄糖的重吸收进而增加尿葡萄糖排泄,从而发挥降糖作用。已有大量研究证实SGLT2抑制剂除发挥降糖作用外,还可在冠心病治疗中获益。本文主要对SGLT2抑制剂治疗T2DM合并冠心病的研究进展及作用机制作一综述。Diabetes is an independent risk factor for coronary heart disease,and the two are mutually causal in disease progression.Sodium-glucose cotransporter 2 inhibitor is a new oral medicine for the treatment of type 2 diabetes mellitus,which can play a hypoglycemic effect by blocking the reabsorption of glucose by the renal proximal convoluted tubules and increasing the excretion of urine glucose.A large number of studies have confirmed that in addition to hypoglycemic effects,SGLT2 inhibitors can also benefit in the treatment of coronary heart disease.This article mainly reviews the research progress and mechanism of SGLT2 inhibitors in the treatment of T2DM complicated with coronary heart disease.

关 键 词：糖尿病 2型 冠心病 钠-葡萄糖共转运蛋白2抑制剂 治疗 综述 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]